Hydroxychloroquine Does Not Increase Bleeding Risk
Hydroxychloroquine (HCQ) does not increase bleeding risk and may actually reduce thrombotic events. The FDA-approved drug label does not list bleeding or hemorrhage as a recognized adverse effect 1. Instead, the documented hematologic toxicities include myelosuppression (aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia) and hemolytic anemia in G6PD-deficient patients—none of which are bleeding disorders 1.
Evidence for Antithrombotic Effects
The clinical evidence actually demonstrates antithrombotic properties of hydroxychloroquine:
A 2022 meta-analysis of 13 randomized controlled trials (2,663 patients) showed HCQ reduced thromboembolic events by 49% (RR 0.51,95% CI 0.31-0.84) 2. This represents a substantial protective effect against clotting, not bleeding.
A 2026 systematic review and meta-analysis in primary antiphospholipid syndrome found that adjunctive HCQ therapy reduced recurrent thrombosis by approximately 65-70% (HR ~0.33) with no increase in major bleeding events 3.
Historical orthopedic studies from the 1970s-1980s demonstrated that HCQ prophylaxis after hip replacement surgery reduced thromboembolism without causing untoward bleeding complications 4, 5.
Mechanism of Action
HCQ's antithrombotic effects work through:
- Inhibition of platelet adhesiveness and aggregation
- Reduction in red blood cell aggregation
- Decreased blood viscosity
- Importantly: these effects do NOT prolong bleeding time 4, 5
Documented Adverse Effects (Not Including Bleeding)
The FDA label and guidelines identify these serious toxicities 1:
Hematologic (non-bleeding):
- Myelosuppression requiring periodic blood count monitoring
- Hemolytic anemia in G6PD deficiency (monitor especially in men of African, Asian, or Middle Eastern origin)
- Thrombocytopenia (low platelets, but bleeding is not a documented clinical consequence)
Other major toxicities:
- Retinal toxicity (dose >5 mg/kg/day, duration >5-10 years) 6, 7
- Cardiomyopathy and QT prolongation 1
- Hypoglycemia 1
- Neuropsychiatric reactions 1
Clinical Implications
When prescribing HCQ, monitor for:
- Complete blood counts periodically (for myelosuppression, not bleeding)
- G6PD levels before starting in at-risk populations
- Ophthalmologic screening (baseline, then annually after 5 years or 1 year if risk factors present) 8, 7
- QT interval if using with other QT-prolonging drugs 9, 1
Do NOT avoid HCQ due to bleeding concerns. The drug is safe regarding hemostasis and may actually provide cardiovascular protection through antithrombotic mechanisms 10, 11. In pregnancy with SLE/APS, HCQ is recommended and does not increase bleeding risk 12, 8, 13.
The only bleeding-related consideration is that severe thrombocytopenia from myelosuppression could theoretically increase bleeding risk, but this is a rare complication requiring drug discontinuation, not a direct bleeding effect of HCQ itself 1.